Table 1.
Baseline characteristics of the study population
| Placebo, n = 17 | VIA‐2291 25 mg, n = 12 | VIA‐2291 50 mg, n = 12 | VIA‐2291 100 mg, n = 13 | All VIA‐2291 Groups, n = 37 | |
|---|---|---|---|---|---|
| Age, y | 55.1 ± 8.3 | 57.6 ± 8.9 | 55.4 ± 9.7 | 54.5 ± 8.2 | 55.8 ± 8.8 |
| Male sex | 13 (76.5) | 10 (83.3) | 11 (91.7) | 12 (92.3) | 33 (89.2) |
| Risk factors | |||||
| HTN | 12 (70.6) | 5 (40.7) | 10 (83.3) | 11 (84.6) | 26 (70.3) |
| Smoking | 9 (60.0) | 5 (71.4) | 10 (83.3) | 8 (72.7) | 23 (76.7) |
| Hyperlipidemia | 4 (26.7) | 0 (0) | 1 (8.33) | 2 (18.2) | 3 (10) |
| DM | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Medications | |||||
| ASA | 17 (100) | 11 (91.7) | 12 (100) | 13 (100) | 36 (97.3) |
| Clopidogrel | 17 (100) | 11 (91.7) | 12 (100) | 13 (100) | 36 (97.3) |
| β‐Blocker | 17 (100) | 10 (83.3) | 10 (83.3) | 13 (100) | 33 (89.2) |
| ACEIs | 9 (52.9) | 4 (33.3) | 9 (75.0) | 10 (76.9) | 23 (62.3) |
| ARBs | 3 (17.7) | 1 (8.3) | 1 (8.3) | 2 (15.4) | 4 (10.8) |
| Statins | 17 (100) | 12 (100) | 12 (100) | 13 (100) | 37 (100) |
| Blood pressure, mm Hg | |||||
| SBP | 111.6 ± 3.2 | 111.5 ± 8.6 | 119.9 ± 13.7 | 111.0 ± 4.0 | 114.0 ± 2.2 |
| DBP | 67.0 ± 9.5 | 66.3 ± 2.5 | 73.3 ± 6.8 | 68.3 ± 8.7 | 69.3 ± 8.0 |
| Lipid values, mg/dL | |||||
| Total cholesterol | 137.01 ± 38.1 | 123.6 ± 22.8 | 111.3 ± 34.9 | 133.9 ± 8.3 | 123.55 ± 30.3 |
| LDL‐C | 85 ± 40.2 | 63.2 ± 16.5 | 63 ± 24.3 | 78.2 ± 20.0 | 68.5 ± 21.2 |
| HDL‐C | 36.8 ± 8.7 | 37.1 ± 14.4 | 34.7 ± 10.4 | 32.0 ± 5.1 | 34.5 ± 10.4 |
| TG | 147.8 ± 69.3 | 192.1 ± 50.0 | 152.4 ± 82.8 | 169.2 ± 83.0 | 171.2 ± 117.6 |
Abbreviations: ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ASA, acetylsalicylic acid (aspirin); DBP, diastolic blood pressure; DM, diabetes mellitus; HDL‐C, high‐density lipoprotein cholesterol; HTN, hypertension; LDL‐C, low‐density lipoprotein cholesterol; SBP, systolic blood pressure; SD, standard deviation; TG, triglycerides; VIA‐2291, atreleuton.
Data are presented as n (%) or mean ± SD.